definition of mucositis
Mucositis is defined as inflammatory and/or ulcerative lesions of the oral and/or gastrointestinal tract usually caused by cancer therapies.
Alimentary tract mucositis refers to the expression of mucosal injury across the continuum of oral and gastrointestinal mucosa, from the mouth to the anus.
risk factors for mucositis
Risk of mucositis has classically been directly associated with modality, intensity and route of delivery of the cancer therapy.
Combination therapy (e.g. head and neck radiation with concurrent chemotherapy) may increase the severity of oral mucositis.
While this modelling continues to be valid, there appear to be additional risk factors (e.g. genetic polymorphisms) in some cohorts that account for degree of clinical expression. This latter component of the risk paradigm is under current investigation and is addressed in the 'Future directions' section of this report. Further study of these more recently defined factors will likely strategically advance the pathobiological model in relation to clinical expression of the toxicity.
mucositis assessment
A variety of assessment scales exist for the measurement of oral mucositis. Most of the scales that are utilized for clinical care incorporate the collective measurement of oral symptoms, signs and functional disturbances. By comparison, some scales are primarily centred in clinician-based observation of mucosal tissue injury (e.g. erythema, ulceration). These latter scales have particular value in clinical trial-based assessment of oral mucositis.
In contrast, there is a limited number of instruments available for assessment of gastrointestinal mucositis. These scales typically measure indirect outcomes of mucosal injury, including diarrhoea. However, interpretation of such data can be confounded by other clinical conditions and interventions that also contribute to the event being measured. New technologies, as described in 'Future directions', may lead to enhanced assessment strategies for gastrointestinal mucositis. mucositis incidence and associated complications incidence of oral mucositis in patients receiving high-dose head and neck radiation Incidence of World Health Organization (WHO) grade 3 or 4 oral mucositis in patients receiving high-dose head and neck radiation to the oral cavity approaches 85%, but all treated patients have some degree of oral mucositis. Mucositis is one of the prime limiting factors of chemoradiation for advanced head and neck carcinoma. The oral pain associated with the lesion frequently leads to the need for enteral nutritional support with or without use of a feeding tube or gastrostomy, as well as use of morphinomimetics, with the objective of maintaining dose intensity throughout the entire radiation regimen.
incidence of oral and gastrointestinal mucositis in patients undergoing haematopoietic stem-cell transplantation
Incidence of WHO grade 3 or 4 oral mucositis can be as high as 75% in patients undergoing haematopoietic stem-cell transplantation (HSCT), depending on the intensity of the conditioning regimen used and the use of methotrexate prophylactically to prevent graft-versus-host disease. Management of oral and gastrointestinal mucositis is one of the main challenges during the period of aplasia, with risk of sepsis related to the degree of mucosal barrier breakdown and depth of marrow suppression.
incidence of mucositis associated with standard multicycle chemotherapy (with or without radiotherapy) for non-Hodgkin's lymphoma and breast, lung and colorectal cancers Data relative to the risk of developing grade 3 or 4 oral mucositis and diarrhoea are presented in Table 1 . For all tumour sites, chemotherapy with 5-fluorouracil (5-FU), capecitabine or tegafur leads to a high rate (e.g. 20%-50%) of alimentary tract mucositis. Recently reported phase I modelling of drug dose and sequence may be of benefit to future patients in this regard. Chemotherapy with methotrexate and other antimetabolites leads to a 20%-60% rate of alimentary tract mucositis according to the drug's given dose per cycle. As described in 'Future directions', recent advances in cancer patient management, including utilization of molecularly targeted cancer therapies, are anticipated to strategically redefine cure rates and adverse event profiles in the coming years. The impact of these agents on the risk of mucosal damage and diarrhoea has yet to be described.
mucositis management guidelines
Oral and gastrointestinal mucositis management guidelines, as developed by the Mucositis Study Group of MASCC/ISOO, are summarized below.
oral mucositis guidelines basic oral care and good clinical practice. Multidisciplinary development and evaluation of oral care protocols that include frequent use of non-medicated oral rinses (e.g. saline mouth rinses 4-6 times/day) is recommended. Patient and staff education in the use of such protocols is recommended for reduction of the severity of oral mucositis from chemotherapy and/or radiation therapy [III, B] .
Interdisciplinary development of systematic oral care protocols is suggested. As part of the protocols, the use of a soft toothbrush that is replaced on a regular basis is also suggested consistent with good clinical practice.
Patient-controlled analgesia with morphine is recommended as the treatment of choice for oral mucositis pain in patients undergoing HSCT [I, A]. Regular oral pain assessment using validated instruments for self-reporting is essential.
In addition to evidence-based recommendations and suggestions published by the MASCC/ISOO, it is relevant to note that topical anaesthetics can provide short-term pain relief for oral mucositis on an empirical basis. gastrointestinal mucositis guidelines basic bowel care and good clinical practice. In addition to the evidence-based guidelines below, basic bowel care should include maintenance of adequate hydration. In addition, consideration should be given to the potential for transient lactose intolerance and the presence of bacterial pathogens. These suggestions are consistent with good clinical practice. The group also addressed the importance of discussing future guideline development and integration with colleagues in other health professional organizations and who have created guidelines more recently, in order to extend the dissemination and utilization of evidence-based mucositis management interventions. Next steps are being planned by the Mucositis Study Group in this regard.
In addition, there continues to be key progress relative to the molecular pathobiology, computational biology and clinical impact of mucosal injury in cancer patients that may generate strategic research and clinical advances in the future. These advances will likely result in revisions in the MASCC/ISOO mucositis guidelines in the next 2-5 years. Examples of novel, important future opportunities based on the recent advances include the following.
Delineation of predictive models that could enhance the ability of clinicians to prospectively identify which solid tumour patients are at highest risk for development of clinically significant oral and/or gastrointestinal mucositis. Recent research relative to identification of systemic and/or mucosal tissue-based genetic susceptibility for mucositis represents an important example of this modelling. Enhanced technologies to assess severity of gastrointestinal mucositis. Utilization of single or combination topical and/or systemic preventive and treatment interventions, once several molecularly targeted therapies for mucositis are approved for clinical use. Increased clinical recognition of the importance of Grade II oral and/or gastrointestinal mucositis, in the context of symptom burdens that are experienced by cancer patients. Potential impact of emerging targeted cancer therapies on the incidence and severity of alimentary tract mucositis.
There is also need and opportunity for the conduct of clinical trials relative to devices that have been initially reported as effective and safe in reducing oral mucositis incidence and severity in cancer patients. Such studies are essential for several reasons including (i) validation of current commercial claims, (ii) identification of which patients may experience highest benefit and (iii) assessment of feasibility for use by these patients.
It is important that basic, translational and clinical research continues relative to preventive and treatment modalities for oral and gastrointestinal mucositis. This collective research could lead to approval of new drugs and devices for which evidence-based, cancer patient-specific identification of risk and associated management of mucositis could become possible.
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